Literature DB >> 984794

Selection and characterization of strains of Staphylococcus aureus displaying unusual resistance to aminoglycosides.

S G Wilson, C C Sanders.   

Abstract

Susceptibility tests with aminoglycosides against Staphylococcus aureus have revealed discrepancies between the minimal inhibitory concentrations and the minimal bactericidal concentrations. To further evaluate these discrepancies, kill curves were performed against a susceptible strain of S. aureus with five different aminoglycosides (amikacin, kanamycin, tobramycin, gentamicin, sisomicin) at concentrations up to 16-fold above the minimal inhibitory concentration. Results revealed the presence of small subpopulations of cells capable of growth within 24 h in concentrations of aminoglycoside up to eightfold above the minimal inhibitory concentration for the parent strain. These subpopulations occurred at a frequency of >/=10(-7) parent cells, were not physiologically different from the susceptible parent strains, and were present in approximately one-half of 30 strains of S. aureus tested. The resistance of these subpopulations was approximately eightfold higher than that of the parent for all five aminoglycosides and was independent of concentration or type of aminoglycoside used to select them. This resistance was not due to extracellular degradation of drug and was stable over eight transfers in drug-free medium, except when selected by gentamicin or sisomicin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 984794      PMCID: PMC429782          DOI: 10.1128/AAC.10.3.519

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Replica plating and indirect selection of bacterial mutants.

Authors:  J LEDERBERG; E M LEDERBERG
Journal:  J Bacteriol       Date:  1952-03       Impact factor: 3.490

Review 2.  Mechanisms of antibiotic resistance in bacteria.

Authors:  R Benveniste; J Davies
Journal:  Annu Rev Biochem       Date:  1973       Impact factor: 23.643

3.  Activity of aminoglycoside antibiotics aganst Pseudomonas aeruginosa: specificity and site of calcium and magnesium antagonism.

Authors:  V M Zimelis; G G Jackson
Journal:  J Infect Dis       Date:  1973-06       Impact factor: 5.226

4.  Antibiotic inhibitors of the bacterial ribosome.

Authors:  B Weisblum; J Davies
Journal:  Bacteriol Rev       Date:  1968-12

5.  Microbiological evaluation of BB-K 8, a new semisynthetic aminoglycoside.

Authors:  K E Price; D R Chisholm; M Misiek; F Leitner; Y H Tsai
Journal:  J Antibiot (Tokyo)       Date:  1972-12       Impact factor: 2.649

6.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

7.  Effects of procedural variations on the activity of aminoglycosides in vitro.

Authors:  C C Sanders; W E Sanders
Journal:  Am J Clin Pathol       Date:  1975-03       Impact factor: 2.493

8.  In vitro evaluation of tobramycin, a new aminoglycoside antibiotic.

Authors:  M E Levison; R Knight; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1972-05       Impact factor: 5.191

9.  Kanamycin 6'-acetate and ribostamycin 6'-acetate, enzymatically inactivated products by Pseudomonas aeruginosa.

Authors:  H Yamamoto; M Yagisawa; H Naganawa; S Kondo; T Takeuchi
Journal:  J Antibiot (Tokyo)       Date:  1972-12       Impact factor: 2.649

10.  Clinical study of the use of the new aminoglycoside tobramycin for therapy of infections due to gram-negative bacteria.

Authors:  G Jaffe; W Ravreby; B R Meyers; S Z Hirschman
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

View more
  13 in total

1.  Agar shake tube technique for simultaneous determination of aerobic and anaerobic susceptibility to antibiotics.

Authors:  J B Evans; L J Harrell
Journal:  Antimicrob Agents Chemother       Date:  1977-10       Impact factor: 5.191

2.  Studies on multi-antibiotic resistant strains of Staphylococcus aureus.

Authors:  H Chmel; A Person; F Tecson-Tumang
Journal:  Infection       Date:  1982       Impact factor: 3.553

3.  Anaerobic resistance of clinical isolates of Staphylococcus aureus to aminoglycosides.

Authors:  L J Harrell; J B Evans
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

4.  Single and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutants.

Authors:  M H Miller; M A Wexler; N H Steigbigel
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

5.  A site-directed Staphylococcus aureus hemB mutant is a small-colony variant which persists intracellularly.

Authors:  C von Eiff; C Heilmann; R A Proctor; C Woltz; G Peters; F Götz
Journal:  J Bacteriol       Date:  1997-08       Impact factor: 3.490

6.  Chronic prosthetic hip infection caused by a small-colony variant of Escherichia coli.

Authors:  A Roggenkamp; A Sing; M Hornef; U Brunner; I B Autenrieth; J Heesemann
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

7.  Two forms of Staphylococcus aureus in blood of patients with staphylococcal sepsis.

Authors:  D M Musher; R E Baughn; E J Young
Journal:  J Clin Microbiol       Date:  1979-01       Impact factor: 5.948

8.  Methicillin potentiates the effect of gentamicin on methicillin-resistant Staphylococcus aureus.

Authors:  R J Hemmer; P Vaudaux; F A Waldvogel
Journal:  Antimicrob Agents Chemother       Date:  1979-01       Impact factor: 5.191

9.  Human infections caused by thiamine- or menadione-requiring Staphylococcus aureus.

Authors:  J F Acar; F W Goldstein; P Lagrange
Journal:  J Clin Microbiol       Date:  1978-08       Impact factor: 5.948

Review 10.  Phenotypic and Genotypic Characteristics of Small Colony Variants and Their Role in Chronic Infection.

Authors:  Benjamin E Johns; Kevin J Purdy; Nicholas P Tucker; Sarah E Maddocks
Journal:  Microbiol Insights       Date:  2015-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.